Abiratas, containing the active ingredient Abiraterone Acetate, is a medication used primarily in the treatment of prostate cancer. It works by inhibiting the production of androgens, hormones that can promote cancer growth.
Abiratas is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy. It can also be used in combination with prednisone to enhance its effectiveness.
Abiraterone acetate functions by blocking the enzyme CYP17, which is crucial in the biosynthesis of androgens. By reducing androgen levels, Abiratas helps slow down the growth of prostate cancer cells.
The recommended dosage of Abiratas is typically 1,000 mg taken orally once daily, in combination with 5 mg of prednisone taken twice daily. It is important to take the medication on an empty stomach, at least one hour before or two hours after food.
Common side effects of Abiratas may include fatigue, hypertension, hot flashes, and joint pain. Patients should be monitored for liver function and signs of adrenal insufficiency during treatment.
Before starting treatment with Abiratas, patients should inform their healthcare provider of any pre-existing conditions, medications, or allergies. Regular follow-up appointments are necessary to assess treatment response and manage any potential side effects.
Abiratas is a vital treatment option for patients with advanced prostate cancer, offering a mechanism to control hormone levels and slow disease progression. Always consult a healthcare professional for personalized medical advice and treatment planning.